Abstract. The presence of circulating tumor cells (CTC) is an independent prognostic factor for progression-free and overall survival for patients with metastatic and newly diagnosed breast cancer. The present study was undertaken to explore whether the presence of CTC before and during follow-up after surgery is associated with recurrence free survival (RFS) and overall survival (OS). In a prospective single center study, CTC were enumerated with the CellSearch system in 30 ml of peripheral blood of 403 stage I-III patients before undergoing surgery for breast cancer (A) and if available 1 week after surgery (B), after adjuvant chemo-and/or radiotherapy or before start of long-term hormonal therapy (C), one (D), two (E) and three (F) years after surgery. Patients were stratified into unfavorable (CTC ≥1) and favorable (CTC=0) prognostic groups. >1 CTC in 30 ml blood was detected in 75/403 (19%) at A, 66/367 (18%) at B, 40/263 (15%) at C, 30/235 (12%) at D, 18/144 (11%) at E and 11/83 (13%) at F. RFS and OS was significantly lower for unfavorable CTC as compared to favorable CTC before surgery (p= 0.022 and p= 0.006), after adjuvant therapy (p<0.001 and p= 0.018) and one (p= 0.006 and p= 0.013) and two (p<0.001 and p= 0.045) years after surgery, but not 1 week post-surgery. The presence of CTC in blood drawn pre and one and two years after surgery, but not post-surgery is associated with shorter RFS and OS for stage I-III breast cancer.
Introduction
patients with non-metastatic breast cancer are treated surgically. Adjuvant treatment is indicated if the risk for recurrence can be significantly reduced. Risk assessment is, thus, of utmost importance and is being conducted by means of TNM-classification and differentiation grade complemented by estrogen and progesterone receptor status, Her2neu expression and peri-tumor vascular invasion (1) (2) (3) (4) (5) . More recent improvement of the risk assessment is obtained through the molecular characterization of the tumor (6) (7) (8) (9) (10) (11) . These methods identify genetic phenotypes with a higher likelihood for micrometastasis that can lead to disease recurrence. Detection of the actual presence of tumor cells beyond the primary tumor is preferred, but may not be sufficient, as one cannot distinguish between dormant tumor cells and those giving rise to recurrence of the disease (12, 13) . The presence of micrometastases in bone marrow of breast cancer patients is associated with an increased risk for disease recurrence and death, but has not been adapted in standard clinical practice (14) (15) (16) . A more attractive approach for the detection of the presence of tumor cells beyond the primary tumor is the detection of circulating tumor cells (CTC). For CTC detection a validated method is available (17) and several studies have demonstrated that the presence of CTC in patients with metastatic breast cancer is associated with a significantly shorter progression free and overall survival (18) (19) (20) (21) . In these studies CTC can be found in 7.5 ml of blood in ~70% of metastatic breast cancer patients. The presence of CTC in the non-metastatic setting is considerable lower and is similar to that found in patients with benign breast disease (22) . Still a relation between their presence and an increased risk of disease recurrence has been shown in several studies (23) (24) (25) (26) (27) . Whether or not this relation also exists when blood is investigated for the presence of tumor cells after surgical removal of the tumor and during follow-up has not yet been investigated. In a previous study we investigated the relation between the presence of CTC before breast cancer surgery and recurrence free survival and breast cancer related survival (22) and in the present study we report the relation between CTC in blood of these patients at several time-points after surgery and extended the follow-up of to a median of 5.7 years. and three (F-Draw) years after surgery to measure CTC. All patients were treated in accordance with the Dutch national guidelines (28) . The ethics board of Medisch Spectrum Twente (Enschede, The Netherlands) approved the study protocol and all patients provided informed consent. The primary endpoint of the present study was an association between the presence of CTC and breast cancer related recurrence and was reported earlier (22) . In the present study, we report the relation between the presence of CTC and recurrence free and overall survival before and at several time-points after surgery. All patient records were reviewed in 2013 and updated for occurrence of breast related disease recurrence and death resulting in a follow-up period of 0.5-9.9 years (median 5.7)
Materials and methods

Study
CellSearch system. The CellSearch system (veridex) was used to measure CTC. Four 7.5-ml aliquots of each patient were analyzed within 72 h after blood draw. This system immunomagnetically enriches CTC from 7. (Table III) . To investigate whether this was due to the difference in the number of patients with blood drawn after surgery the same analysis was done for the blood drawn of these 367 patients taken before surgery and is shown in italics in Table III . This clearly shows that the presence of CTC in the same group of patients is highly significant in the blood drawn before, but not after surgery. After completion of adjuvant therapy blood was drawn in 263 of the 348 patients that received adjuvant therapy. Presence of CTC was significantly associated with RFS and OS (Table III) . presence of CTC in blood drawn 1 year (n=245) and 2 years (n=162) after surgery was also significantly associated with RFS and OS (Table III) . This significant difference was not reached in the same group of patients when considering the CTC in the blood drawn presurgery. The presence of CTC in 83 patients with blood drawn 3 years after surgery was not significantly associated with RFS and OS (Table III) . Fig. 2 shows the kaplan-Meier plots for OS for patients with and without CTC after surgery ( Fig. 2A ), 1 year after surgery (Fig. 2B ), 2 years after surgery and 3 years after surgery (Fig. 2D) .
Multivariate analysis for disease recurrence and survival.
Multivariate logistic regression analysis was performed to identify the parameters most significant for RFS and OS of breast cancer patients. For this the univariate significant parameters for RFS and OS were used. Table Iv shows this analysis in which conditionally stepwise elimination of least significant parameters was applied for recurrence RFS and OS.
Discussion
Several studies have shown that the presence of tumor cells in blood of breast cancer patients before surgery (22, 24, 25, 27) and with metastatic disease (18) (19) (20) is associated with poor outcome. To simplify the interpretation of the CTC results patients with metastatic disease are subdivided into those with favorable CTC (<5/7.5 ml of blood) and those with unfavorable CTC (>5/7.5 ml of blood) (18) . In actuality, the peripheral blood circulating tumor cell load reflects the prognosis of the patient and the larger the CTC load the lower the survival time (30, 31) . By fitting the distribution of the CTC frequency in patients with metastatic disease in whom CTC were detected it was calculated that a 10-fold increase in CTC corresponds to a decrease in survival of 6.6 month and suggested that this trend continues at CTC concentrations that cannot be detected with current technology (31) . Efforts are ongoing to determine whether CTC indeed can be identified in all patients with metastatic carcinomas by probing larger blood volumes for the presence of CTC (32, 33) . To detect a breast cancer tumor before the disease is disseminated using circulating tumor cells will be even more challenging (34) . One of the largest difficulties is the discrimination between those tumor cells that can cause harm and those that may remain dormant. This is exemplified by the presence of micro-metastasis in the bone marrow in ~30% of patients at the time of diagnosis, but although their presence is associated with an increased risk for disease recurrence not all of the patients with micrometastasis will develop a disease recurrence (15, 16) . Likewise, not all patients in which CTC are detected before surgery will develop a disease recurrence (22, 25, 35) . Aneusomie of CTC has been demonstrated in patients suspect for dormant breast cancer suggesting that at least some of these cells are indeed (18) 40 (15) 30 (12) 18 (11) 11 (13) 1 48 (12) 33 (9) 31 (12) 21 (9) 13 (8) 9 (11) 2 4 (1) 12 (3) 6 (2) 4 (2) 2 (1)
12 (3) 9 (3) 3 (1) 4 (2) 3 (3) 1 (1) a Long-term hormonal therapy is not included in the adjuvant therapy. For each time-point during follow-up (FU) the recurrence free survival (RFS) and overall survival (OS) for this subset of patients was also calculated from the before surgery draw analysis (shown in italics). tumor cells but in a dormant state (12) . Furthermore, cells classified as CTC can also be detected at low frequency in patients with benign disease suggesting that they may not be tumor cells which can explain part of the absence of recurrence in CTC positive patients with cancer (22) .
In the present study, we investigated the presence of CTC in 30 ml of blood before and during follow-up after surgery to determine whether CTC could be detected and whether or not their presence after surgery was still related to poor outcome. Results of the pre-surgery blood were presented before (22) , but here we extended the follow-up and investigated the role of CTC in blood drawn during 3 years of follow-up. The longer follow-up increased the significance of the presence of CTC and CTC are highly significant in multivariate analysis for OS. The proportion of patients with CTC detected before surgery (19%) was not different in the weeks after surgery (18%). Surprisingly, CTC presence was highly significant for RFS (p= 0.022) and OS (p= 0.006) in blood draw pre-surgery, but not in the post-surgery blood for RFS (p= 0.852) and OS (p= 0.182). Possible explanations are that the cells detected in the post-surgery blood are epithelial cells or tumor cells with no metastatic potential shed during surgery. Alternatively, these cells are similar to those observed in patients with benign disease (22) . Remarkably, the same phenomenon is observed in patients undergoing surgery for colorectal cancer (36).
presence of CTC in blood drawn after adjuvant therapy, but before starting long-term hormonal therapy was highly significant for both RFS (p<0.001) and OS (p= 0.018). This may not be surprising as this patient group already has a higher risk for disease recurrence as compared to those not receiving adjuvant. This significance was, however, also observed in the patient group comprising patients that did not receive adjuvant therapy as the presence of CTC was significant for RFS and OS in blood drawn one and two years after surgery. Remarkably, CTC in blood of the same patients drawn before surgery was not significant. These results indeed indicate a potential important role for the monitoring of patients treated for breast cancer, but also highlight that improvement of CTC technology is needed before it can play a role in clinical practice. Relative simple improvement in CTC technology can be obtained by automation of the assignment of objects as CTC and optimization of the definition by which the human error and subjectivity can be eliminated (37) . Further needed is confirmation at the genetic level that the cells identified as CTC are indeed tumor cells. Technology to detect genetic abnormalities associated with cancer in CTC is indeed feasible (12, 33, (38) (39) (40) (41) (42) (43) but will need to be implemented in this setting. Still remaining is the challenge to discriminate between those tumor cells signifying impeding relapse and those that do not (44) . Availability of larger numbers of CTC will help to address these questions and be obtained by probing larger blood volumes for the presence of CTC (30, 33, 34) and alternative phenotypes (45, 46) or physical characteristics (47) (48) (49) .
In conclusion, CTC found in the blood at several time-points after surgery for breast cancer extends our knowledge to what already has been shown for CTC detection before surgery, it is also associated with a shorter RFS and OS. However, improvement in the determination and characterization of CTC is necessary in order to design randomized trials guiding the effect of the adjuvant therapy or starting pre-emptive therapy in those patients with presence of CTC after surgery.
